{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T00:23:47Z","timestamp":1718497427482},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,15]]},"DOI":"10.7759\/cureus.62425","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T13:12:23Z","timestamp":1718457143000},"source":"Crossref","is-referenced-by-count":0,"title":["An Adolescent Case of Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis With Interstitial Lung Disease Successfully Treated by Multitarget Therapy Avoiding Cyclophosphamide: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Tadafumi","family":"Yokoyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsumi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Sakumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Tasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taizo","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Juvenile Dermatomyositis and Other Inflammatory Muscle Diseases","author":"Pilkington CA","year":"2021","unstructured":"Pilkington CA, Feldman BM, Sontichai W. Juvenile Dermatomyositis and Other Inflammatory Muscle Diseases. Textbook of Pediatric Rheumatology. Petty RE, Laxer RM, Lindsley CB, et al (ed): Elsevier, Philadelphia, PA; 2021. 360-76."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep375","article-title":"The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody","volume":"49","author":"Nakashima R","year":"2010","unstructured":"Nakashima R, Imura Y, Kobayashi S, et al.. The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010, 49:433-40. 10.1093\/rheumatology\/kep375","journal-title":"Rheumatology (Oxford)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316651748","article-title":"Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease","volume":"25","author":"Nakashima R","year":"2016","unstructured":"Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus. 2016, 25:925-33. 10.1177\/0961203316651748","journal-title":"Lupus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies","volume":"12","author":"Nombel A","year":"2021","unstructured":"Nombel A, Fabien N, Coutant F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol. 2021, 12:773352. 10.3389\/fimmu.2021.773352","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Bellutti Enders F","year":"2017","unstructured":"Bellutti Enders F, Bader-Meunier B, Baildam E, et al.. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017, 76:329-40. 10.1136\/annrheumdis-2016-209247","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh082","article-title":"Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety","volume":"43","author":"Riley P","year":"2004","unstructured":"Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford). 2004, 43:491-6. 10.1093\/rheumatology\/keh082","journal-title":"Rheumatology (Oxford)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s004670000523","article-title":"A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children","volume":"16","author":"Latta K","year":"2001","unstructured":"Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol. 2001, 16:271-82. 10.1007\/s004670000523","journal-title":"Pediatr Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70408-5","article-title":"Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study","volume":"15","author":"Green DM","year":"2014","unstructured":"Green DM, Liu W, Kutteh WH, et al.. Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. Lancet Oncol. 2014, 15:1215-23. 10.1016\/S1470-2045(14)70408-5","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu385","article-title":"Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis","volume":"54","author":"Kobayashi N","year":"2015","unstructured":"Kobayashi N, Takezaki S, Kobayashi I, et al.. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology (Oxford). 2015, 54:784-91. 10.1093\/rheumatology\/keu385","journal-title":"Rheumatology (Oxford)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-023-02747-3","article-title":"Efficacy and safety of multi-target therapy in children with lupus nephritis","volume":"94","author":"Zheng X","year":"2023","unstructured":"Zheng X, Ouyang X, Cheng C, Rong L, Chen L, Mo Y, Jiang X. Efficacy and safety of multi-target therapy in children with lupus nephritis. Pediatr Res. 2023, 94:2040-6. 10.1038\/s41390-023-02747-3","journal-title":"Pediatr Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.09.006","article-title":"Tacrolimus use in lupus nephritis: A systematic review and meta-analysis","volume":"15","author":"Hannah J","year":"2016","unstructured":"Hannah J, Casian A, D'Cruz D. Tacrolimus use in lupus nephritis: A systematic review and meta-analysis. Autoimmun Rev. 2016, 15:93-101. 10.1016\/j.autrev.2015.09.006","journal-title":"Autoimmun Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison AC","year":"2000","unstructured":"Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000, 47:85-118. 10.1016\/s0162-3109(00)00188-0","journal-title":"Immunopharmacology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer A","year":"2013","unstructured":"Fischer A, Brown KK, Du Bois RM, et al.. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013, 40:640-6. 10.3899\/jrheum.121043","journal-title":"J Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-022-00785-5","article-title":"Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance","volume":"21","author":"Sherman MA","year":"2023","unstructured":"Sherman MA, Kim H, Banschbach K, et al.. Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance. Pediatr Rheumatol Online J. 2023, 21:3. 10.1186\/s12969-022-00785-5","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","unstructured":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021, 100.S1-S276. 10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis A","year":"2020","unstructured":"Fanouriakis A, Kostopoulou M, Cheema K, et al.. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020, 79:713-23. 10.1136\/annrheumdis-2020-216924","journal-title":"Ann Rheum Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007121272","article-title":"Successful treatment of class V+IV lupus nephritis with multitarget therapy","volume":"19","author":"Bao H","year":"2008","unstructured":"Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008, 19:2001-10. 10.1681\/ASN.2007121272","journal-title":"J Am Soc Nephrol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04398-2","article-title":"Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review","volume":"39","author":"Huang K","year":"2019","unstructured":"Huang K, Vinik O, Shojania K, Yeung J, Shupak R, Nimmo M, Avina-Zubieta JA. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review. Rheumatol Int. 2019, 39:1971-81. 10.1007\/s00296-019-04398-2","journal-title":"Rheumatol Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4122-2","article-title":"Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis","volume":"37","author":"So H","year":"2018","unstructured":"So H, Wong VT, Lao VW, Pang HT, Yip RM. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis. Clin Rheumatol. 2018, 37:1983-9. 10.1007\/s10067-018-4122-2","journal-title":"Clin Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2017.1334814","article-title":"Describing and expanding the clinical phenotype of anti-MDA5-associated rapidly progressive interstitial lung disease: case series of nine Canadian patients and literature review","volume":"47","author":"Hoa S","year":"2018","unstructured":"Hoa S, Troyanov Y, Fritzler MJ, et al.. Describing and expanding the clinical phenotype of anti-MDA5-associated rapidly progressive interstitial lung disease: case series of nine Canadian patients and literature review. Scand J Rheumatol. 2018, 47:210-24. 10.1080\/03009742.2017.1334814","journal-title":"Scand J Rheumatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2017.1314004","article-title":"Effectiveness of multi-target therapy in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with early-stage interstitial lung disease","volume":"46","author":"Suda M","year":"2017","unstructured":"Suda M, Kataoka Y, Tomishima Y, Jinta T, Rokutanda R, Kishimoto M, Okada M. Effectiveness of multi-target therapy in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with early-stage interstitial lung disease. Scand J Rheumatol. 2017, 46:505-6. 10.1080\/03009742.2017.1314004","journal-title":"Scand J Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2020.101299","article-title":"Erythematous auricular papules in the fatal cases of anti-MDA5 antibody-positive interstitial lung disease","volume":"31","author":"Intapiboon P","year":"2020","unstructured":"Intapiboon P, Siripaitoon B. Erythematous auricular papules in the fatal cases of anti-MDA5 antibody-positive interstitial lung disease. Respir Med Case Rep. 2020, 31:101299. 10.1016\/j.rmcr.2020.101299","journal-title":"Respir Med Case Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2015.07.004","article-title":"Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140\/MDA5 antibody positive amyopathic dermatomyositis","volume":"109","author":"Takada T","year":"2015","unstructured":"Takada T, Aoki A, Asakawa K, Sakagami T, Moriyama H, Narita I, Sato S. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140\/MDA5 antibody positive amyopathic dermatomyositis. Respir Med. 2015, 109:1174-80. 10.1016\/j.rmed.2015.07.004","journal-title":"Respir Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1080\/24725625.2020.1810398","article-title":"A case of anti-MDA5 antibody-positive dermatomyositis developing reversible cerebral vasospasm syndrome successfully treated by multi-immunosuppressant combination including mycophenolate mofetil","volume":"5","author":"Muramatsu T","year":"2021","unstructured":"Muramatsu T, Tono T, Kanayama Y, et al.. A case of anti-MDA5 antibody-positive dermatomyositis developing reversible cerebral vasospasm syndrome successfully treated by multi-immunosuppressant combination including mycophenolate mofetil. Mod Rheumatol Case Rep. 2021, 5:69-75. 10.1080\/24725625.2020.1810398","journal-title":"Mod Rheumatol Case Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-021-00595-1","article-title":"Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review","volume":"19","author":"Yeung TW","year":"2021","unstructured":"Yeung TW, Cheong KN, Lau YL, Tse KN. Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review. Pediatr Rheumatol Online J. 2021, 19:103. 10.1186\/s12969-021-00595-1","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21833","article-title":"Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: A case series","volume":"36","author":"Saito T","year":"2021","unstructured":"Saito T, Mizobuchi M, Miwa Y, et al.. Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: A case series. J Clin Apher. 2021, 36:196-205. 10.1002\/jca.21833","journal-title":"J Clin Apher"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05530-5","article-title":"Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy","volume":"40","author":"Ge Y","year":"2021","unstructured":"Ge Y, Li S, Tian X, He L, Lu X, Wang G. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. Clin Rheumatol. 2021, 40:2311-7. 10.1007\/s10067-020-05530-5","journal-title":"Clin Rheumatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1159\/000346573","article-title":"Response of mucocutaneous lesions to rituximab in a case of melanoma differentiation antigen 5-related dermatomyositis","volume":"225","author":"Clottu A","year":"2012","unstructured":"Clottu A, Laffitte E, Prins C, Chizzolini C. Response of mucocutaneous lesions to rituximab in a case of melanoma differentiation antigen 5-related dermatomyositis. Dermatology. 2012, 225:376-80. 10.1159\/000346573","journal-title":"Dermatology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.235","article-title":"Cytokine profiles of amyopathic dermatomyositis with interstitial lung diseases treated with mycophenolate","volume":"5","author":"Hayashi M","year":"2017","unstructured":"Hayashi M, Aoki A, Asakawa K, Sakagami T, Kikuchi T, Takada T. Cytokine profiles of amyopathic dermatomyositis with interstitial lung diseases treated with mycophenolate. Respirol Case Rep. 2017, 5:e00235. 10.1002\/rcr2.235","journal-title":"Respirol Case Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.56.7956","article-title":"Dermatomyositis with rapidly progressive interstitial lung disease treated with rituximab: A report of 3 cases in Japan","volume":"56","author":"Tokunaga K","year":"2017","unstructured":"Tokunaga K, Hagino N. Dermatomyositis with rapidly progressive interstitial lung disease treated with rituximab: A report of 3 cases in Japan. Intern Med. 2017, 56:1399-403. 10.2169\/internalmedicine.56.7956","journal-title":"Intern Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.2328-18","article-title":"Interstitial lung disease with anti-melanoma differentiation-associated protein 5 antibody: Rapidly progressive perilobular opacity","volume":"58","author":"Chino H","year":"2019","unstructured":"Chino H, Sekine A, Baba T, et al.. Interstitial lung disease with anti-melanoma differentiation-associated protein 5 antibody: Rapidly progressive perilobular opacity. Intern Med. 2019, 58:2605-13. 10.2169\/internalmedicine.2328-18","journal-title":"Intern Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejr.2021.02.003","article-title":"Subacute cutaneous lupus erythematosus, and positive anti-MDA5 antibody in clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease: A case report and literature review","volume":"43","author":"Sulaiman W","year":"2021","unstructured":"Sulaiman W, Heng YHA, Lee BR, Subramaniam R. Subacute cutaneous lupus erythematosus, and positive anti-MDA5 antibody in clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease: A case report and literature review. Egyptian Rheumatol. 2021, 43:197-202. 10.1016\/j.ejr.2021.02.003","journal-title":"Egyptian Rheumatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13136","article-title":"Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis","volume":"20","author":"Hisanaga J","year":"2017","unstructured":"Hisanaga J, Kotani T, Fujiki Y, Yoshida S, Takeuchi T, Makino S. Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis. Int J Rheum Dis. 2017, 20:2182-5. 10.1111\/1756-185X.13136","journal-title":"Int J Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/259960-an-adolescent-case-of-anti-mda5-antibody-positive-juvenile-dermatomyositis-with-interstitial-lung-disease-successfully-treated-by-multitarget-therapy-avoiding-cyclophosphamide-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T13:12:27Z","timestamp":1718457147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/259960-an-adolescent-case-of-anti-mda5-antibody-positive-juvenile-dermatomyositis-with-interstitial-lung-disease-successfully-treated-by-multitarget-therapy-avoiding-cyclophosphamide-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.62425","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,15]]}}}